Cue Biopharma, Inc. (CUE) competitors & alternatives
Health Care · NASDAQ
Cue Biopharma, Inc. (CUE)'s top competitors and alternatives — its most similar public companies — include LYELL IMMUNOPHARMA INC (LYEL), ARCUS BIOSCIENCES INC (RCUS), JANUX THERAPEUTICS INC (JANX), CELLDEX THERAPEUTICS INC (CLDX), DIANTHUS THERAPEUTICS INC (DNTH), FORTE BIOSCIENCES INC (FBRX), CRISPR THERAPEUTICS AG (CRSP), JADE BIOSCIENCES INC (JBIO), SAB BIOTHERAPEUTICS INC (SABS), KYVERNA THERAPEUTICS INC (KYTX), CONTEXT THERAPEUTICS INC (CNTX) and AVALO THERAPEUTICS INC (AVTX). These are Cue Biopharma, Inc.'s closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top CUE competitors & alternatives
-
LYELL IMMUNOPHARMA INCLYELHealth Care
Late-stage clinical cell therapy company engineering next-generation dual-targeting CD19/CD20 CAR T-cell therapies for blood cancers and solid tumors, with a…
$12.84 (as of 2026-07-22) · market cap $315M
-
ARCUS BIOSCIENCES INCRCUSHealth Care
A clinical-stage biotech developing first-in-class and best-in-class small molecules and antibodies for cancer immunotherapy, with lead HIF-2α inhibitor in…
$29.97 (as of 2026-07-22) · market cap $3.7B
-
JANUX THERAPEUTICS INCJANXHealth Care
Janux Therapeutics is a clinical-stage biotech developing next-generation, tumor-activated bispecific immunotherapies to improve the safety and efficacy of…
$15.62 (as of 2026-07-22) · market cap $953M
-
CELLDEX THERAPEUTICS INCCLDXHealth Care
A clinical-stage biopharmaceutical company developing mast cell-targeted monoclonal and bispecific antibodies for chronic urticaria, inflammatory skin…
$34.77 (as of 2026-07-22) · market cap $2.7B
-
DIANTHUS THERAPEUTICS INCDNTHHealth Care
Dianthus Therapeutics is a clinical-stage biopharmaceutical company developing targeted complement-pathway inhibitors to treat severe autoimmune and…
$102.76 (as of 2026-07-22) · market cap $5.7B
-
FORTE BIOSCIENCES INCFBRXHealth Care
A clinical-stage biotech developing an anti-CD122 antibody (FB102) to modulate immune cells in autoimmune diseases, with promising early celiac disease data…
$56.63 (as of 2026-07-22) · market cap $1.2B
-
CRISPR THERAPEUTICS AGCRSPHealth Care
CRISPR Therapeutics develops gene-editing medicines using CRISPR/Cas9 technology, with the first approved CRISPR therapy (CASGEVY) for sickle cell disease and…
$47.24 (as of 2026-07-22) · market cap $4.6B
-
JADE BIOSCIENCES INCJBIOHealth Care
Jade Biosciences is a clinical-stage biotech developing next-generation monoclonal antibodies with extended half-lives to treat autoimmune diseases like IgA…
$19.85 (as of 2026-07-22) · market cap $1.2B
-
SAB BIOTHERAPEUTICS INCSABSHealth Care
SAB Biotherapeutics produces fully human polyclonal antibodies via engineered cattle to treat autoimmune diseases, with SAB-142 in Phase 2b trials for type 1…
$3.58 (as of 2026-07-22) · market cap $278M
-
KYVERNA THERAPEUTICS INCKYTXHealth Care
Kyverna is a clinical-stage immunology biotech developing novel investigational therapeutics with no approved products and complete dependence on successful…
$7.40 (as of 2026-07-22) · market cap $452M
-
CONTEXT THERAPEUTICS INCCNTXHealth Care
Clinical-stage biopharmaceutical company developing T-cell engaging bispecific antibodies to treat solid tumors by redirecting immune cells against cancer…
$0.61 (as of 2026-07-22) · market cap $56M
-
AVALO THERAPEUTICS INCAVTXHealth Care
Clinical-stage biotech developing abdakibart, a humanized anti-IL-1β antibody for hidradenitis suppurativa with Phase 2 data readout expected mid-2026.
$18.15 (as of 2026-07-22) · market cap $961M
Not quite? Describe exactly what you want →
Peers are Cue Biopharma, Inc.'s closest public companies by shared sub-industry, sector and business themes. See the full profile: Cue Biopharma, Inc. (CUE).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.